CION Ameerpet
Multidisciplinary Sarcoma Care · MDT · NABH Accredited
The Sarcoma Tumour Board & How Multidisciplinary Care Works
When you are deciding where to be treated for a sarcoma, one question matters more than the name of any single surgeon: is your case discussed by a tumour board before treatment starts? A sarcoma tumor board — also called a multidisciplinary team, or MDT — is a meeting where the surgeon, radiation oncologist, medical oncologist, radiologist and pathologist sit together, look at the same scans and biopsy slides, and agree one written plan and the exact order of treatment. For a cancer this rare and this varied, that single decision shapes whether the tumour is removed with clear margins, whether the limb is saved, and ultimately how likely the cancer is to come back. This page explains who sits on the board, what they decide, and how CION runs its multidisciplinary sarcoma board across 7 NABH-accredited Hyderabad locations.
- One plan, agreed before treatment — not a series of separate opinions collected one doctor at a time
- The right sequence — whether radiation or chemotherapy comes before surgery is decided up front
- Scans and slides re-read by specialists — sarcoma radiology and pathology before any incision
- Guideline-backed — NCCN and ESMO recommend MDT review for every sarcoma at a specialist centre
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
What Is a Sarcoma Tumour Board?
A sarcoma tumour board is a formal, scheduled meeting at which every specialist who could be involved in your treatment reviews your case together, at the same table, and agrees a single plan before anything is done. It is also called a multidisciplinary team meeting, or MDT. Instead of seeing a surgeon on Monday, a radiation oncologist on Thursday, and a chemotherapy doctor the next week — each forming an opinion in isolation — the board puts them all in one room with your MRI on the screen and your biopsy slides under the microscope, and asks one question: what is the best whole-journey plan for this person, and in what order should it be delivered?
This matters more for sarcoma than for almost any other cancer. Sarcoma is rare — under 1% of adult cancers — and has more than 70 subtypes, each behaving differently. A liposarcoma in the thigh, a GIST in the stomach, and an osteosarcoma in the knee are all called "sarcoma," but the right treatment, the right drugs, and even the right surgeon differ completely. No single doctor holds expert, current knowledge of all of them. The board is how a centre pools that expertise so your rare subtype is handled by people who actually treat it.
International guidelines reflect this. Both the NCCN and ESMO recommend that every sarcoma — ideally before the very first biopsy — be managed by a multidisciplinary team at a specialist centre. That is precisely why treatment at a specialist sarcoma centre matters: the board is not an optional extra, it is the engine driving every other good decision. You can see how this fits the wider picture on our sarcoma — overview hub.
Did You Know? The most powerful question a patient can ask a hospital is, "Will my case be discussed at a sarcoma tumour board before treatment starts?" If the honest answer is no — or "we'll decide as we go" — that is a strong signal you are not yet at a specialist centre. Patients whose plan is set by an MDT before the first operation consistently have higher rates of clear surgical margins and better limb preservation.
Who Sits on the Multidisciplinary Sarcoma Board?
A true sarcoma MDT is not just two or three doctors. It is a fixed group of specialists who each bring one essential piece of the picture, and who only reach a sound plan when all the pieces are on the table at once:
Surgical Oncologist
Decides whether the tumour is resectable, what margin is achievable, and whether the limb can be preserved. Leads the operative plan.
Radiation Oncologist
Advises whether radiation is needed and, crucially, when — before surgery to sterilise the tumour edge, or after to treat a close margin.
Medical Oncologist
Identifies subtypes that respond to chemotherapy or targeted therapy — GIST, Ewing sarcoma, rhabdomyosarcoma — and times systemic treatment.
Musculoskeletal Radiologist
Re-reads the MRI, CT and PET, maps the tumour to nerves and vessels, and confirms the stage — often catching detail a general report misses.
Sarcoma Pathologist
Confirms the exact subtype and grade from the biopsy using specialist immunohistochemistry — the diagnosis the whole plan rests on.
Reconstructive & Allied Team
Reconstructive surgery for large defects, plus physiotherapy, oncology nursing and the coordinator who keeps your journey on schedule.
The reason all six matter together is sequence. If the radiation oncologist recommends pre-operative radiation but is consulted only after the surgeon has already operated, that option is gone forever. If the pathologist later reclassifies the tumour as a subtype that needs chemotherapy first, the patient has lost a chance the board would have caught. The MDT exists so no good option is closed off by an accident of timing.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get One Clear Plan From the Whole Team
Whether you are newly diagnosed or already part-way through treatment elsewhere, our multidisciplinary sarcoma board will review your scans, slides and history together and tell you the best plan and the right sequence — across 7 Hyderabad locations with same-week appointments.
What Actually Happens in a Sarcoma MDT Meeting?
The patient is rarely in the room, but the decisions made there govern everything that follows. At CION, a sarcoma case moves through the board in four clear stages:
1. Confirm the Diagnosis
The pathologist presents the biopsy — exact subtype, grade, and the molecular markers that define it — while the radiologist presents the imaging: size, depth, and the tumour's relationship to nerves, vessels and bone. Surprisingly often, a tumour referred as "probable benign lump" is reclassified here as a sarcoma, and the whole plan changes. Nothing else is decided until the diagnosis is locked down.
2. Agree the Stage and the Intent
The team confirms the stage — including whether a chest CT or PET scan has ruled out spread to the lungs, the most common site of sarcoma metastasis. They then agree the intent: a curative plan aimed at removing the tumour completely, or one focused on control and quality of life. Honest agreement on intent prevents over-treatment and under-treatment alike.
3. Decide the Modalities and the Sequence
This is the heart of multidisciplinary care. The board decides which treatments are needed — surgery, radiation, chemotherapy, or a combination — and the exact order. For many soft tissue sarcomas that is neoadjuvant (pre-surgery) radiation, then wide excision, then a margin review; for a chemo-sensitive subtype like Ewing sarcoma it may be chemotherapy first. Getting the sequence right is what makes limb-sparing surgery and clear margins possible.
4. Write It Down and Re-Present
The agreed plan is documented and explained to you in plain language. Critically, the case comes back to the board at key moments — after surgery when the final margin report is in, or whenever a scan changes — so the plan is updated by the whole team, not quietly altered by one doctor.
Did You Know? The most damaging mistake in sarcoma is an "unplanned excision" — a lump removed by a general surgeon before anyone knew it was a sarcoma. With no MDT reviewing it first, the margins are usually inadequate and the surgical bed contaminated, often forcing a much bigger re-operation. Discussing a deep, growing, or painless lump at a tumour board before it is touched is the surest way to avoid this — which is why guidelines push for MDT review even before the biopsy.
Why the Tumour Board Changes Outcomes
Multidisciplinary review is not bureaucracy — for a treatment decider, it is the most reliable sign that the plan you are offered is the right one.
Right diagnosis
Fewer Misdiagnoses
Specialist pathology and radiology re-reading the case together catch reclassifications a single general report misses — and the diagnosis is what every later decision rests on.
Right order
Correct Treatment Sequence
Deciding up front whether radiation or chemotherapy comes before surgery preserves every option — and makes margin-clear, limb-sparing surgery achievable rather than a hope.
No lost time
One Coordinated Journey
A single agreed plan removes the weeks lost shuttling between unconnected doctors, with a named coordinator keeping surgery, radiation and chemotherapy on schedule.
If a single doctor has given you a sarcoma plan and no one has mentioned a tumour board, that is not a reason to panic — but it is a strong reason to seek a second opinion from a centre that runs one. A board does not just confirm a good plan; it catches the ones that would have quietly gone wrong.
How CION Runs Its Multidisciplinary Sarcoma Board
At CION, the tumour board is the standard pathway for every sarcoma — not a meeting reserved for the most complex cases. Once your scans and biopsy reach us, your case is put before a fixed multidisciplinary team led by our AIIMS-trained surgical oncologist, Dr. Muralidhar Muddusetty, alongside radiation oncology, medical oncology, specialist radiology and pathology. Because all of our specialties sit within one connected Hyderabad network, the board can convene quickly — important when a growing sarcoma should not wait weeks for separate appointments.
For patients from outside Hyderabad, or those who already hold a plan from another hospital, CION offers a free written second opinion built on the same board process: you send your MRI, biopsy report and any existing plan, the team reviews it together, and you receive a clear written summary of the recommended treatment and its sequence — so you can decide with confidence rather than on the word of a single consultant.
What You Should Bring to a Board Review
| Item | Why the Board Needs It |
|---|---|
| MRI of the tumour site (with films/CD, not just the report) | So the radiologist can re-read it and map the tumour to nerves, vessels and bone |
| Biopsy slides & pathology report | So the sarcoma pathologist can confirm the exact subtype and grade |
| Chest CT or PET scan (if done) | To check for spread to the lungs and complete the staging |
| Any treatment plan already given | So the board can review, confirm or correct an existing recommendation |
| Operative notes (if a lump was already removed) | To assess margins and decide whether a re-excision is needed |
Don't have everything? Send what you have — the board will tell you which test is needed before a plan can be finalised. EMI options and cashless support through major TPAs, Aarogyasri, CGHS, ECHS & ESI are available for eligible patients.
A note for treatment deciders: the board's value is greatest before the first treatment — especially before any surgery. If a deep, firm, or growing lump has not yet been removed, presenting it to the board first prevents an unplanned excision and protects every later option. The board is most powerful as a starting point, not a rescue.
Why Patients Choose CION's Multidisciplinary Sarcoma Care
For a rare cancer with 70-plus subtypes, the board is the safeguard that no single doctor can replace. Here is why patients trust CION to get the whole plan right.
Tumour board for every sarcoma
AIIMS-trained surgical oncologist
Surgery, radiation & medical oncology together
Specialist sarcoma pathology & radiology
Free written second opinion
One named coordinator
7 NABH-accredited Hyderabad locations
EMI facility & insurance accepted
4.8 / 5 Google rating
Take The Next Step
Let the Whole Team Decide Your Plan
A sarcoma plan agreed by a multidisciplinary board — before treatment starts — gives you the best chance of clear margins, a saved limb, and the lowest risk of recurrence. If you are newly diagnosed or unsure about an existing plan, talk to us first.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
The Sarcoma Tumour Board — Frequently Asked Questions
What is a sarcoma tumor board?
A sarcoma tumor board — also called a multidisciplinary team (MDT) meeting — is a scheduled meeting where every specialist who could be involved in your care reviews your case together at the same time. The surgical oncologist, radiation oncologist, medical oncologist, a specialist radiologist and a sarcoma pathologist look at the same MRI, CT/PET scans and biopsy slides, confirm the diagnosis and stage, and agree a single written treatment plan and the exact sequence of treatment before anything is done. Because sarcoma is rare and has more than 70 subtypes, both NCCN and ESMO guidelines recommend that every sarcoma be managed this way at a specialist sarcoma centre.
Who attends a multidisciplinary sarcoma MDT?
A full sarcoma MDT brings together a surgical oncologist (who plans the operation and margin), a radiation oncologist (who decides whether and when radiation is given), a medical oncologist (for chemotherapy or targeted therapy in sensitive subtypes), a musculoskeletal radiologist (who re-reads the imaging and confirms the stage), and a sarcoma pathologist (who confirms the exact subtype and grade). Reconstructive surgery, oncology nursing, physiotherapy and a patient coordinator are also part of the wider team. The point is that all of them contribute before the plan is fixed, so no good treatment option is lost to bad timing.
Why does multidisciplinary sarcoma care lead to better outcomes?
Sarcoma is rare and highly varied, so no single doctor can be expert in every subtype, and the order of treatment matters enormously. A tumour board reduces misdiagnosis by having specialist pathology and radiology re-read the case, and it locks in the correct treatment sequence — for example, deciding up front whether radiation or chemotherapy should come before surgery. That sequencing is what makes margin-clear, limb-sparing surgery achievable. Patients whose plan is agreed by an MDT before the first operation consistently have higher rates of clear margins and better limb preservation than those treated without one.
Do I need to attend the tumour board meeting in person?
No. The board reviews your scans, biopsy slides and history — you are not usually present in the meeting itself. What matters is that the right materials reach the team: ideally your MRI films (not just the report), your biopsy slides and pathology report, any chest CT or PET scan, and any treatment plan you have already been given. After the board has met, the agreed plan is explained to you in plain language, with the reasoning behind each step, in your own consultation.
I already have a sarcoma treatment plan from another hospital — is a board review still useful?
Yes, and it is one of the most valuable things you can do. If your plan was made by a single doctor without an MDT, a board review can confirm it is sound or catch a problem before treatment locks the situation in — particularly before any surgery, which is hardest to undo. CION offers a free written second opinion built on the same board process: you send your scans, biopsy report and existing plan, the multidisciplinary team reviews them together, and you receive a written recommendation. This is exactly the situation a specialist second opinion exists for.